Latest news with #ARSPharmaceuticals'
Yahoo
26-03-2025
- Business
- Yahoo
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Analysts Are Reducing Their Forecasts For This Year
The latest analyst coverage could presage a bad day for ARS Pharmaceuticals, Inc. (NASDAQ:SPRY), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. Revenue and earnings per share (EPS) forecasts were both revised downwards, with analysts seeing grey clouds on the horizon. Surprisingly the share price has been buoyant, rising 14% to US$13.15 in the past 7 days. Whether the downgrade will have a negative impact on demand for shares is yet to be seen. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Following the latest downgrade, the current consensus, from the six analysts covering ARS Pharmaceuticals, is for revenues of US$83m in 2025, which would reflect a perceptible 6.8% reduction in ARS Pharmaceuticals' sales over the past 12 months. After this downgrade, the company is anticipated to report a loss of US$1.36 in 2025, a sharp decline from a profit over the last year. However, before this estimates update, the consensus had been expecting revenues of US$125m and US$0.36 per share in losses. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase. See our latest analysis for ARS Pharmaceuticals There was no major change to the consensus price target of US$29.50, signalling that the business is performing roughly in line with expectations, despite lower earnings per share forecasts. Another way we can view these estimates is in the context of the bigger picture, such as how the forecasts stack up against past performance, and whether forecasts are more or less bullish relative to other companies in the industry. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 6.8% by the end of 2025. This indicates a significant reduction from annual growth of 126% over the last three years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 20% annually for the foreseeable future. It's pretty clear that ARS Pharmaceuticals' revenues are expected to perform substantially worse than the wider industry. The most important thing to take away is that analysts increased their loss per share estimates for this year. Regrettably, they also downgraded their revenue estimates, and the latest forecasts imply the business will grow sales slower than the wider market. We're also surprised to see that the price target went unchanged. Still, deteriorating business conditions (assuming accurate forecasts!) can be a leading indicator for the stock price, so we wouldn't blame investors for being more cautious on ARS Pharmaceuticals after the downgrade. Still, the long-term prospects of the business are much more relevant than next year's earnings. At Simply Wall St, we have a full range of analyst estimates for ARS Pharmaceuticals going out to 2027, and you can see them free on our platform here. Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Yahoo
21-03-2025
- Business
- Yahoo
ARS Pharmaceuticals Full Year 2024 Earnings: Beats Expectations
Revenue: US$89.1m (up by US$89.1m from FY 2023). Net income: US$8.00m (up from US$54.4m loss in FY 2023). Profit margin: 9.0% (up from net loss in FY 2023). The move to profitability was driven by higher revenue. EPS: US$0.083 (up from US$0.57 loss in FY 2023). We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates significantly. Earnings per share (EPS) also surpassed analyst estimates. Looking ahead, revenue is forecast to grow 34% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are up 21% from a week ago. While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We have a graphic representation of ARS Pharmaceuticals' balance sheet and an in-depth analysis of the company's financial position. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
Reuters
05-03-2025
- Health
- Reuters
US FDA expands use of allergic reaction nasal spray in people between 15-30 kilograms
March 5 (Reuters) - The U.S. Food and Drug Administration approved the expanded use of ARS Pharmaceuticals' (SPRY.O), opens new tab nasal spray for severe allergic reactions in patients who weigh between 15 and 30 kilograms, the company said on Wednesday. Shares of the company were up 4.5% in extended trading. The spray, sold under the brand name neffy, will be dosed at 1 milligram (mg) for the new patient population, compared to the previously approved dose of 2 mg for people who weigh above 30 kilograms. Neffy, which was first approved by the FDA in August, is seen as an alternative to EpiPen and other autoinjectors that are filled with epinephrine. It is designed to be given at the first sign of a severe allergic reaction to prevent life-threatening conditions such as anaphylaxis. Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
